191 related articles for article (PubMed ID: 24924771)
1. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.
Wu Y; Liu HB; Shi XF; Song Y
PLoS One; 2014; 9(6):e99577. PubMed ID: 24924771
[TBL] [Abstract][Full Text] [Related]
2. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies.
Thakkar B; Aronis KN; Vamvini MT; Shields K; Mantzoros CS
Metabolism; 2013 Jul; 62(7):922-34. PubMed ID: 23419783
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
4. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Nie SP; Chen H; Zhuang MQ; Lu M
Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538
[TBL] [Abstract][Full Text] [Related]
5. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
[TBL] [Abstract][Full Text] [Related]
6. Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.
Mekuria AN; Ayele Y; Tola A; Mishore KM
J Diabetes Res; 2019; 2019():7676909. PubMed ID: 31828167
[TBL] [Abstract][Full Text] [Related]
7. Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis.
Xin WX; Fang L; Fang QL; Zheng XW; Ding HY; Huang P
Medicine (Baltimore); 2018 Mar; 97(9):e0035. PubMed ID: 29489653
[TBL] [Abstract][Full Text] [Related]
8. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
9. Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis.
Zhou JB; Tang X; Han M; Yang J; Simó R
Metabolism; 2020 Aug; 109():154265. PubMed ID: 32446679
[TBL] [Abstract][Full Text] [Related]
10. Sulfonylurea and fracture risk in patients with type 2 diabetes mellitus: A meta-analysis.
Zhang Z; Cao Y; Tao Y; E M; Tang J; Liu Y; Li F
Diabetes Res Clin Pract; 2020 Jan; 159():107990. PubMed ID: 31866530
[TBL] [Abstract][Full Text] [Related]
11. Antidiabetic Medications and the Risk of Endometrial Cancer in Patients.
Tian J; Liang Y; Qu P
Gynecol Obstet Invest; 2019; 84(5):455-462. PubMed ID: 30808843
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Pladevall M; Riera-Guardia N; Margulis AV; Varas-Lorenzo C; Calingaert B; Perez-Gutthann S
BMC Cardiovasc Disord; 2016 Jan; 16():14. PubMed ID: 26769243
[TBL] [Abstract][Full Text] [Related]
13. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; McWilliams RR; Chari ST
Am J Gastroenterol; 2013 Apr; 108(4):510-9; quiz 520. PubMed ID: 23399556
[TBL] [Abstract][Full Text] [Related]
14. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
Gebrie D; Getnet D; Manyazewal T
Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
[TBL] [Abstract][Full Text] [Related]
16. Metformin Use and Lung Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis.
Yao L; Liu M; Huang Y; Wu K; Huang X; Zhao Y; He W; Zhang R
Dis Markers; 2019; 2019():6230162. PubMed ID: 30881522
[TBL] [Abstract][Full Text] [Related]
17. Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias.
Bowker SL; Lin M; Eurich DT; Johnson JA
Can J Diabetes; 2017 Apr; 41(2):204-210. PubMed ID: 27908558
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.
Wu L; Zhu J; Prokop LJ; Murad MH
Sci Rep; 2015 Jun; 5():10147. PubMed ID: 26076034
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis.
Foroutan N; Muratov S; Levine M
Clin Invest Med; 2016 Apr; 39(2):E48-62. PubMed ID: 27040861
[TBL] [Abstract][Full Text] [Related]
20. Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis.
Zhao Z; He X; Sun Y
Front Pharmacol; 2023; 14():1193610. PubMed ID: 37497113
[No Abstract] [Full Text] [Related]
[Next] [New Search]
